Literature DB >> 6887655

Effect of splenectomy and immunotherapy on advanced gastric cancer associated with total gastrectomy.

H Miwa, K Kojima, F Ono, T Kobayashi, T Tsurumi, A Hatosaki, T Iijima, K Orita.   

Abstract

Immunotherapy with levamisole (LMS) and combined splenectomy were performed in the cases of stages III and IV gastric cancer of the upper and middle stomach and associated with total gastrectomy. The cell-mediated immunity and the survival rates for both groups were compared with controls. Combined splenectomy was not effective for cases of stage III gastric cancer, but was effective for those in stage IV. Comparing the cumulative survival rates of the immunotherapy group with the controls, cases of stages III and IV gastric cancer without splenectomy, the survival rate of those with immunotherapy was higher than that of the control group in the cases of the stage III, but the result was reverse in cases of stage IV gastric cancer. Changes in the cell-mediated immunity correlated with the survival rates.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6887655     DOI: 10.1007/bf02469685

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  8 in total

1.  STUDIES ON MOUSE ANTIBODIES. I. THE RESPONSE TO SHEEP RED CELLS.

Authors:  F L ADLER
Journal:  J Immunol       Date:  1965-07       Impact factor: 5.422

Review 2.  Levamisole in the modulation of the immune response: the current experimental and clinical state.

Authors:  J Symoens; M Rosenthal
Journal:  J Reticuloendothel Soc       Date:  1977-03

3.  Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas.

Authors:  I Hellström; K E Hellström; H O Sjögren
Journal:  Cell Immunol       Date:  1970-05       Impact factor: 4.868

4.  The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification.

Authors:  T Kajitani
Journal:  Jpn J Surg       Date:  1981-03

5.  Novel broad-spectrum anthelmintics. Tetramisole and related derivatives of 6-arylimidazo[2,1-b]thiazole.

Authors:  A H Raeymaekers; F T Allewijn; J Vandenberk; P J Demoen; T T Van Offenwert; P A Janssen
Journal:  J Med Chem       Date:  1966-07       Impact factor: 7.446

6.  The human splenic suppressor cell.

Authors:  D Sampson; C Grotelueschen; H M Kauffman
Journal:  Transplantation       Date:  1975-11       Impact factor: 4.939

7.  Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas.

Authors:  S Yu; D R Lannin; A L Tsui-Collins; C F McKhann
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

8.  Immunochemotherapy of gastric cancer with levamisole.

Authors:  H Miwa; F Ono; M Moriyama; T Kobayashi; T Oka; K Nakamura; K Orita
Journal:  Acta Med Okayama       Date:  1980-09       Impact factor: 0.892

  8 in total
  3 in total

1.  Two-color flow cytometric analysis of splenic lymphocyte subpopulations in patients with gastric cancer.

Authors:  M Takahashi; S Fujimoto; M Takai; K Ohno; F Endoh; Y Masuda; Y Masuda; G Obata
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

2.  Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer.

Authors:  S Saji; J Sakamoto; S Teramukai; K Kunieda; Y Sugiyama; Y Ohashi; H Nakazato
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Effectiveness and safety of splenectomy for gastric carcinoma: a meta-analysis.

Authors:  Kun Yang; Xin-Zu Chen; Jian-Kun Hu; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.